STOCK TITAN

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags

RedHill Biopharma has secured U.S. government funding through BARDA to advance opaganib for Ebola treatment. The funding will support the development of opaganib as a medical countermeasure (MCM) for Ebola virus disease (EBOV). Recent U.S. Army-funded studies showed that opaganib significantly increased survival in an EBOV model. Opaganib is a novel, potentially broad-acting drug with mutation-resistant antiviral and anti-inflammatory activity.

The development comes as there is an urgent need for effective and usable therapies for EBOV, which has a fatality rate of around 50% according to WHO. Opaganib represents an alternative host-directed therapeutic strategy for biodefense and global health preparedness. The drug is also being developed for other indications, including COVID-19, ARDS, and radiological and chemical protection.

RedHill Biopharma ha ottenuto finanziamenti dal governo degli Stati Uniti attraverso il BARDA per promuovere opaganib nel trattamento dell'Ebola. I finanziamenti supporteranno lo sviluppo di opaganib come contro misura medica (MCM) per la malattia da virus Ebola (EBOV). Recenti studi finanziati dall'Esercito degli Stati Uniti hanno dimostrato che opaganib aumenta significativamente la sopravvivenza in un modello di EBOV. Opaganib è un farmaco innovativo, con potenziali azioni ampie, caratterizzato da attività antivirale e antinfiammatoria resistente alle mutazioni.

Lo sviluppo avviene in un contesto di urgente bisogno di terapie efficaci e utilizzabili per l'EBOV, che ha un tasso di mortalità di circa il 50% secondo l'OMS. Opaganib rappresenta una strategia terapeutica alternativa diretta all'ospite per la biodefesa e la preparazione alla salute globale. Il farmaco è inoltre in fase di sviluppo per altre indicazioni, tra cui COVID-19, ARDS e protezione radiologica e chimica.

RedHill Biopharma ha conseguido financiamiento del gobierno de EE. UU. a través de BARDA para avanzar en opaganib para el tratamiento del Ébola. El financiamiento apoyará el desarrollo de opaganib como contramedida médica (MCM) para la enfermedad por virus Ebola (EBOV). Estudios recientes financiados por el Ejército de EE. UU. mostraron que opaganib aumentó significativamente la supervivencia en un modelo de EBOV. Opaganib es un medicamento novedoso, con una acción potencialmente amplia, que presenta actividad antiviral y antiinflamatoria resistente a mutaciones.

Este desarrollo surge ante la urgente necesidad de terapias efectivas y utilizables para el EBOV, que tiene una tasa de mortalidad de alrededor del 50% según la OMS. Opaganib representa una estrategia terapéutica alternativa dirigida al huésped para la biodefensa y la preparación de la salud global. El medicamento también se está desarrollando para otras indicaciones, incluyendo COVID-19, ARDS y protección radiológica y química.

RedHill Biopharma는 에볼라 치료를 위한 opaganib의 개발을 진전시키기 위해 BARDA를 통해 미국 정부의 자금을 확보했습니다. 이 자금은 에볼라 바이러스 질병(EBOV)에 대한 의료 대응책(MCM)으로서 opaganib의 개발을 지원할 것입니다. 최근 미국 육군에서 자금을 지원한 연구에 따르면 opaganib은 EBOV 모델에서 생존율을 크게 증가시켰습니다. Opaganib은 돌연변이에 저항하는 항바이러스 및 항염증 작용을 가진 혁신적인 잠재력 있는 광범위 작용 약물입니다.

이 개발은 WHO에 따르면 약 50%의 치사율을 가진 EBOV에 대한 효과적이고 사용 가능한 치료법의 긴급한 필요성이 대두되는 가운데 이루어집니다. Opaganib은 생물 방어 및 글로벌 건강 준비를 위한 대체 숙주 지향 치료 전략을 나타냅니다. 이 약물은 또한 COVID-19, ARDS, 방사선 및 화학 보호 등을 포함한 다른 적응증을 위해 개발되고 있습니다.

RedHill Biopharma a obtenu des financements du gouvernement américain par le biais de BARDA pour faire avancer opaganib dans le traitement de l'Ébola. Ce financement soutiendra le développement d'opaganib en tant que contre-mesure médicale (MCM) contre la maladie à virus Ebola (EBOV). Des études récentes financées par l'armée américaine ont montré qu'opaganib augmentait significativement la survie dans un modèle d'EBOV. Opaganib est un nouveau médicament à action potentiellement large, présentant une activité antivirale et anti-inflammatoire résistante aux mutations.

Le développement intervient alors qu'il existe un besoin urgent de thérapies efficaces et utilisables pour l'EBOV, qui a un taux de létalité d'environ 50 % selon l'OMS. Opaganib représente une stratégie thérapeutique alternative dirigée vers l'hôte pour la biodéfense et la préparation à la santé mondiale. Le médicament est également en cours de développement pour d'autres indications, notamment le COVID-19, l'ARDS et la protection radiologique et chimique.

RedHill Biopharma hat durch BARDA Fördermittel der US-Regierung gesichert, um opaganib zur Behandlung von Ebola voranzutreiben. Die Finanzierung wird die Entwicklung von opaganib als medizinische Gegenmaßnahme (MCM) gegen die Ebola-Virus-Krankheit (EBOV) unterstützen. Jüngste, mit Mitteln der US-Armee finanzierte Studien zeigten, dass opaganib die Überlebensrate in einem EBOV-Modell signifikant erhöhte. Opaganib ist ein neuartiges, potenziell breit wirksames Medikament mit mutationsresistenter antiviraler und entzündungshemmender Aktivität.

Die Entwicklung erfolgt vor dem Hintergrund eines dringenden Bedarfs an effektiven und anwendbaren Therapien gegen EBOV, dessen Sterblichkeitsrate laut WHO bei etwa 50 % liegt. Opaganib stellt eine alternative, wirtsgerichtete therapeutische Strategie für Biodefense und globale Gesundheitsvorbereitung dar. Das Medikament wird auch für andere Indikationen entwickelt, darunter COVID-19, ARDS sowie radiologischen und chemischen Schutz.

Positive
  • Secured U.S. government funding through BARDA for opaganib development
  • Opaganib showed statistically significant increase in survival in EBOV model
  • Potential for opaganib to be first host-directed molecule to show activity in EBOV
  • Opaganib demonstrated synergistic effect with remdesivir in EBOV study
  • Multiple potential applications for opaganib in various indications
Negative
  • None.

Insights

The selection of opaganib by BARDA for joint development and funding as a medical countermeasure against Ebola virus disease is a significant milestone. This development addresses a critical gap in our biodefense arsenal, as currently approved treatments for Ebola are to monoclonal antibodies, which present logistical challenges in outbreak scenarios.

Opaganib's potential as an oral, small-molecule therapy with mutation-resistant properties could revolutionize Ebola treatment strategies. Its demonstrated efficacy in U.S. Army-funded studies, showing a statistically significant increase in survival in an EBOV model, is particularly promising. The drug's dual antiviral and anti-inflammatory actions, coupled with its potential impact on vascular health, align well with the pathophysiology of Ebola.

For investors, this BARDA contract not only provides immediate funding but also validates the potential of RedHill's pipeline. It opens doors for further government collaborations and enhances the company's position in the biodefense sector. However, it's important to note that the development process under the Animal Rule pathway can be lengthy and complex.

This BARDA contract represents a significant opportunity for RedHill Biopharma. It not only provides important funding for opaganib's development but also lends credibility to the company's research efforts. The selection by a prestigious government agency like BARDA could attract attention from other potential partners and investors.

Financially, while the exact contract value isn't disclosed, such government funding typically reduces R&D expenses for the company, potentially improving its cash position. For a company with a market cap of about $10 million, this kind of support is substantial.

The broader implications of opaganib's potential success extend beyond Ebola. Its demonstrated efficacy against a range of indications, including COVID-19 and ARDS, suggests a versatile pipeline asset. This versatility could translate into multiple revenue streams if the drug proves successful in clinical trials.

However, investors should remain cautious. Drug development, especially for complex diseases like Ebola, is inherently risky. The path to approval, even under the Animal Rule, can be long and uncertain.

The U.S. government's Biomedical Advanced Research and Development Authority (BARDA) selected opaganib for joint development & funding as a medical countermeasure (MCM) to treat Ebola virus disease (EBOV)
--
The funding advances opaganib's positive development progress to date on the expected FDA Animal Rule pathway toward potential approval as an MCM for EBOV
--
Recent U.S. Army-funded studies showed that opaganib delivered a statistically significant increase in survival in an in vivo EBOV model. The BARDA research and development contract provides initial funding for the collaboration, in pursuit of advancing opaganib to mitigate infection and contain EBOV outbreaks
--
This year marks the 10th anniversary of the West Africa Ebola epidemic in which 11,000 people died, and there is still an urgent need for effective and useable therapies, with EBOV proving fatal in around half of all cases according to the World Health Organization (WHO)1
--
Opaganib, a novel potentially broad-acting drug, has shown mutation-resistant antiviral and anti-inflammatory activity, likely to directly impact vascular health - one of the main targets for EBOV dysfunction. It is believed to be the first host-directed molecule to show activity in EBOV in vivo and represents an alternative host-directed therapeutic strategy for biodefense and global health preparedness. Additional U.S. government collaborations with opaganib are ongoing
--
Significant geopolitical and logistical challenges exist in managing outbreaks of disease and there is an urgent need for safe and effective, oral, small molecule therapeutics that can be stored and easily distributed and administered in an outbreak

TEL-AVIV, Israel and RALEIGH, N.C., Oct. 14, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S. government's Biomedical Advanced Research and Development Authority (BARDA), a center of the Department of Health and Human Services (HHS)' Administration for Strategic Preparedness and Response (ASPR), has selected opaganib2 for development to treat exposure to Ebola virus disease (EBOV).

RedHill Biopharma Logo

Under this cost-sharing contract, BARDA will provide partial funding for the company to further advance opaganib to mitigate infection and contain EBOV outbreaks. To date, opaganib has made positive development progress on the expected Animal Rule pathway towards potential approval as a treatment for EBOV. The Animal Rule allows for the use of pivotal animal model efficacy studies to support U.S. Food and Drug Administration (FDA) approval of new drugs when human clinical trials are not ethical or feasible.

"EBOV is deadly, killing, on average, half of all those who contract it. This year marks 10 years since the West Africa Ebola epidemic in which 11,000 people died, and yet there are still no host-directed, small molecule therapies approved to provide effective and useable treatment strategies," said Guy Goldberg, RedHill's Chief Business Officer. "Currently only Inmazeb™, a combination of three monoclonal antibodies, and Ebanga™, a single monoclonal antibody, are FDA-approved to treat EBOV, as such there is an urgent medical need for additional effective and easy to distribute and administer EBOV therapies. There are also enormous geopolitical and logistical challenges to overcome in managing outbreaks such as EBOV, and others like Mpox, and so new host-directed, small molecule therapeutic options for biodefense and global health preparedness could prove to be major life-saving advances – this is especially true if they are capable of viral mutation-resistance, have extended shelf-lives for long-term storage, are relatively straightforward to transport to hard-to-reach territories, and are easy to administer without the need for cold-storage or injections."

Opaganib delivered a statistically significant increase in survival time when given at 150 mg/kg twice a day (BID) in a United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in vivo EBOV study, making it the first host-directed molecule to show activity in EBOV. Opaganib also recently demonstrated a distinct synergistic effect when combined individually with remdesivir (Veklury®, Gilead Sciences Inc.), significantly improving potency while maintaining cell viability, in a U.S. Army-funded and conducted in vitro EBOV study.

Opaganib is currently also in development for multiple oncology, viral, inflammatory and diabetes and obesity-related indications, including COVID-19, acute respiratory distress syndrome (ARDS) and radiological and chemical protection or mitigation.

This project is supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50124C00059.

About Ebola virus disease:
According to the Centers for Disease Control and Prevention (CDC), Ebola disease is a rare and often deadly illness, caused by infection by one of a group of four viruses, known as ebolaviruses. Transmission of the disease is mostly through contact with an infected animal (bat or nonhuman primate) or a sick or dead person infected with an ebolavirus. The course of the illness typically progresses from "dry" symptoms initially (such as fever, aches and pains, and fatigue), and then progresses to "wet" symptoms (such as diarrhea, vomiting and unexplained hemorrhaging, bleeding or bruising) as the person becomes sicker. Currently only Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn, Regeneron Pharmaceuticals, Inc.), a combination of three monoclonal antibodies and Ebanga™ (ansuvimab-zykl, Ridgeback Biotherapeutics, LP), a single monoclonal antibody, are FDA-approved to treat EBOV. Both are intravenously administered direct acting monoclonal antibody antivirals that bind to glycoproteins on the Ebola virus's surface to prevent the virus from entering a person's cells. There is an urgent need for host-directed small molecule therapies that may be effective against multiple strains of ebolavirus, less likely to be impacted by viral mutation, and that are easy to store, distribute and administer, especially in areas where healthcare services and infrastructures may be sub-optimal. 

About Opaganib (ABC294640)
Opaganib, a proprietary investigational host-directed and potentially broad-acting drug, is a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory and antiviral activity, targeting multiple potential indications, including several cancers, diabetes and obesity-related disorders, gastrointestinal acute radiation syndrome (GI-ARS), Sulfur Mustard exposure, COVID-19, Ebola and other viruses as part of pandemic preparedness.

Opaganib's host-directed action is thought to work through the inhibition of multiple pathways, the induction of autophagy and apoptosis, and disruption of viral replication, through simultaneous inhibition of three sphingolipid-metabolizing enzymes in human cells (SPHK2, DES1 and GCS).

Opaganib has been selected for evaluation by multiple NIH-funded U.S. government countermeasures programs: The Radiation and Nuclear Countermeasures Program (RNCP), led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the HHS National Institutes of Health, for the nuclear medical countermeasures (MCM) product development pipeline selected opaganib for development as a potential treatment for Acute Radiation Syndrome (ARS). Opaganib will also be evaluated as a potential countermeasure for inhalational Sulfur Mustard exposure under a joint screening core operated by the BARDA Chemical Medical Countermeasures (Chem MCM) Program and the NIH/NIAID Chemical Countermeasures Research Program (CCRP).

Opaganib has demonstrated antiviral activity against SARS-CoV-2, multiple variants, and several other viruses, such as Influenza A and Ebola.

Being host-targeted, and based on data accumulated to date, opaganib is expected to maintain effect against emerging viral variants. In prespecified analyses of Phase 2/3 clinical data in hospitalized patients with moderate to severe COVID-19, oral opaganib demonstrated improved viral RNA clearance, faster time to recovery and significant mortality reduction in key patient subpopulations versus placebo on top of standard of care. Opaganib has demonstrated its safety and tolerability profile in more than 470 people in multiple clinical studies and expanded access use. Data from the opaganib global Phase 2/3 study was published in Microorganisms.

Opaganib has received several orphan-drug designations from the FDA in oncology and other diseases and has undergone studies in advanced cholangiocarcinoma (Phase 2a) and prostate cancer. Opaganib also has a Phase 1 chemoradiotherapy study protocol ready for FDA-IND submission.

Opaganib has also shown positive preclinical results in renal fibrosis, and has the potential to target multiple oncology, radioprotection, viral, inflammatory, and gastrointestinal indications.

About RedHill Biopharma
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drug Talicia®, for the treatment of Helicobacter pylori (H. pylori) infection in adults3. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class oral broad-acting, host-directed SPHK2 selective inhibitor with potential for pandemic preparedness, targeting multiple indications with a U.S. government collaboration for development for Acute Radiation Syndrome (ARS), a Phase 2/3 program for hospitalized COVID-19, and a Phase 2 program in oncology; (ii) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19, with non-dilutive external funding covering the entirety of the RHB-107 arm of the 300-patient Phase 2 adaptive platform trial, and is also targeting multiple other cancer and inflammatory gastrointestinal diseases; (iii) RHB-102, with potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting, positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; and (v) RHB-204, a Phase 3-stage program for pulmonary nontuberculous mycobacteria (NTM) disease.

More information about the Company is available at www.redhillbio.com / X.com/RedHillBio.

Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include among others, statements regarding the potential effects of opaganib in the treatment of Ebola and other indications. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions; the Company's ability to maintain compliance with the Nasdaq Capital Market's listing requirements; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for opaganib for any indication; the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that the FDA pre-study requirements will not be met and/or that the Phase 3 study of RHB-107 in COVID-19 outpatients will not be approved to commence or if approved, will not be completed or, should that be the case, that we will not be successful in obtaining alternative non-dilutive development funding for RHB-107; the risk that RHB-107's late-stage development for non-hospitalized COVID-19 will not benefit from the resources redirected from the terminated RHB-204 Phase 3 study, and that the Phase 2/3 COVID-19 study for RHB-107 may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional COVID-19 studies for opaganib and RHB-107 are likely to be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of a commercial companion diagnostic for the detection of MAP; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia®; (v) the Company's ability to successfully commercialize and promote Talicia® and Aemcolo®; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 8, 2024. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

Company contact:
Adi Frish
Chief Corporate & Business Development Officer
RedHill Biopharma
+972-54-6543-112
adi@redhillbio.com 

Category: R&D

1 https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease
2
Opaganib is an investigational new drug, not available for commercial distribution.
3 Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: www.Talicia.com.

Logo - https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg

Cision View original content:https://www.prnewswire.com/news-releases/redhill-biopharma-secures-us-government-funding-through-barda-to-advance-opaganib-for-ebola-treatment-302275029.html

SOURCE RedHill Biopharma Ltd.

FAQ

What is the purpose of BARDA's funding for RedHill Biopharma's opaganib (RDHL)?

BARDA's funding is to advance opaganib as a medical countermeasure (MCM) to treat Ebola virus disease (EBOV). The funding supports further development to mitigate infection and contain EBOV outbreaks.

What were the results of recent U.S. Army-funded studies on opaganib for EBOV (RDHL)?

Recent U.S. Army-funded studies showed that opaganib delivered a statistically significant increase in survival in an in vivo EBOV model. It also demonstrated a synergistic effect when combined with remdesivir in an in vitro EBOV study.

How does opaganib differ from current EBOV treatments (RDHL)?

Opaganib is potentially the first host-directed, small molecule therapy for EBOV. Current FDA-approved treatments are monoclonal antibody-based. Opaganib offers advantages in storage, distribution, and administration compared to existing options.

What other indications is RedHill Biopharma developing opaganib for (RDHL)?

Besides EBOV, RedHill Biopharma is developing opaganib for multiple oncology, viral, inflammatory, and diabetes and obesity-related indications. This includes COVID-19, acute respiratory distress syndrome (ARDS), and radiological and chemical protection or mitigation.

Redhill Biopharma Ltd.

NASDAQ:RDHL

RDHL Rankings

RDHL Latest News

RDHL Stock Data

10.63M
12.81B
11.49%
0.57%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Tel Aviv